Ocular Therapeutix (OCUL) Earnings Call Presentation

AXPAXLI for Wet AMD - AXPAXLI aims to redefine the wet AMD market with its highly selective pan-VEGF inhibition and sustained drug delivery via ELUTYX technology[29, 31] - The SOL-1 trial is designed as a superiority study comparing a single dose of AXPAXLI to a single 2mg dose of aflibercept at Week 36, with topline data expected in Q1 2026[45, 48] - The SOL-R trial is designed as a non-inferiority study comparing AXPAXLI Q24W to aflibercept 2mg Q8W at Week 56, with a non-inferiority margin of -45 letters in BCVA[50] - As of January 10, 2025, 311 subjects were enrolled in the SOL-R trial across various stages of loading and randomization[53] - Phase 1 data showed 100% rescue-free rate per protocol at 6 months and 80% at 10 months in a US wet AMD trial with AXPAXLI treatment[39, 41, 111] AXPAXLI for Diabetic Retinopathy (DR) - In the U S, 72% of the 88 million DR patients have NPDR, but less than 1% of NPDR patients are treated[61] - Phase 1 HELIOS study of AXPAXLI in NPDR showed no disease progression to PDR or CI-DME in the AXPAXLI arm at Week 48, compared to 375% in the sham arm[72] Market and Financial Considerations - There are 16 million people with wet AMD in the U S [16] - The company's strong cash position of $3921 million is expected to fund operations into 2028[124]